

We are building a vibrant, sustainable company with the goal of delivering transformational medicines.

#### **Arena Pharmaceuticals Clinical Trials**

**IBD** 

# ELEVATE

## CULTIVATE

**NOW ENROLLING** 

ADDRESSING THE ROOT OF

CROHN'S DISEASE (CD)

program evaluating the efficacy

and safety of once-daily, oral

etrasimod in patients with CD.

**CULTIVATE** is a clinical

**NOW ENROLLING** 

## RISE UP AGAINST ULCERATIVE COLITIS (UC)

**ELEVATE UC** is a worldwide, Phase 3 clinical program (consisting of 3 trials) evaluating the efficacy and safety of once-daily, oral etrasimod in patients with moderately to severly active UC.

**Etrasimod** Etrasimod is an investigational once-daily, oral S1P receptor modulator designed to selectively target S1P1, S1P4, and S1P5. Preclinical studies have shown no observed activity for S1P2 and S1P3 at therapeutic doses.

LEARN MORE **ArenalBD.com** 

#### arenapharm.com

© 2020 Arena Pharmaceuticals, Inc. Arena Pharmaceuticals and Arena are registered service marks of Arena Pharmaceuticals, Inc. All Rights Reserved. 08/2020: MLR-AU-NP-0001 **IBS PAIN** 

# CAPTIVATE



**CAPTIVATE** is a Phase 2 clinical program evaluating the efficacy and safety of oral olorinab in patients experiencing abdominal pain associated with IBS.

**Olorinab** is an investigational, oral, peripherally acting, highly selective, full agonist of the cannabinoid receptor 2.

